UP

Novavax COVID-19 vaccine more than 90% effective in U.S. trial

Home page World
12 Punto 14 Punto 16 Punto 18 Punto

Novavax Inc on Monday said its COVID-19 vaccine was more than 90% effective, including against a variety of concerning variants of the coronavirus in a large, late-stage U.S.-based clinical trial.

Axar.az reports that the study of nearly 30,000 volunteers in the United States and Mexico puts Novavax on track to file for emergency authorization in the United States and elsewhere in the third quarter of 2021, the company said.

The protein-based vaccine was more than 93% effective against the more easily transmissible predominant coronavirus variants that have caused concern among scientists and public health officials, Novavax said.

Protein-based vaccines are a conventional approach that use purified pieces of the virus to spur an immune response, such as those used against whooping cough and shingles.

Date
2021.06.14 / 23:32
Author
Axar.az
See also

Monsoon floods sweep away 18 people and bridge in Nepal

Netanyahu nominates Trump for Nobel Peace Prize

France's Macron makes state visit to the UK

Trump threatens extra tariff on nations siding with BRICS

Switzerland pledges $6.3B to rebuild Ukraine

The US arms review covers all countries

5-magnitude earthquake hits Turkiye

Iran denies supporting plot against Trump

Macron hints at possible 2032 presidential run

Forest fire erupts in Turkiye

Latest
Xocalı soyqırımı — 1992-ci il Bağla
Bize yazin Bağla
ArxivBağla